MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.

Area of Science:

• Oncology
• Hematology
• Molecular Biology

Background:

• Activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) involves chronic B-cell receptor signaling and nuclear factor κB (NF-κB) pathway activation.
• The MYD88 L265P mutation is implicated in NF-κB overactivity in ABC-DLBCL.
• The relationship between MYD88 protein expression and the MYD88 L265P mutation in DLBCL remains understudied.

Purpose of the Study:

• To investigate MYD88 protein expression and MYD88 L265P mutation status in DLBCL specimens.
• To correlate MYD88 expression and mutation with clinicopathologic features and patient outcomes.

Main Methods:

• Immunohistochemistry was used to assess MYD88 protein expression in 124 DLBCL samples.
• Polymerase chain reaction and direct DNA sequencing were employed to detect the MYD88 L265P mutation.
• Statistical analyses were performed to evaluate associations with clinical parameters and survival.

Main Results:

• MYD88 overexpression was observed in 38.7% of DLBCL cases, localized in the cytoplasm.
• MYD88 overexpression correlated with older age and increased tumor recurrence.
• Overexpression was an independent predictor of shortened disease-free survival (DFS) in DLBCL patients.
• The MYD88 L265P mutation was present in 6.5% of cases, predominantly in non-germinal center B-cell-like DLBCL, and showed no association with MYD88 expression or clinicopathologic parameters.

Conclusions:

• High MYD88 protein expression is a significant prognostic factor associated with tumor recurrence and reduced DFS in DLBCL.
• MYD88 appears crucial for lymphoma progression, irrespective of the MYD88 L265P mutation status.
• The incidence of the MYD88 L265P mutation in the studied Korean population was lower than previously reported.